Kairos Pharma Reports $1.4 Million Net Loss in Q3 2025, Increases Operating Expenses

Kairos Pharma, Ltd. reported its financial results for the third quarter of 2025, revealing a net loss of $1.4 million for the three months ending September 30, compared to a loss of $1.05 million during the same period in 2024. For the nine months ended September 30, 2025, the company incurred a net loss of $4.08 million, significantly higher than the $1.62 million loss reported for the same period in the previous year. The company has not generated any revenue during these periods, maintaining its status as a clinical-stage biopharmaceutical firm focused on developing immunotherapy and cell therapy treatments for oncology.

Operating expenses for the third quarter of 2025 totaled $1.44 million, up from $383,000 in the prior year, driven primarily by increased research and development costs, which rose to $608,000 from $14,000. General and administrative expenses also increased to $827,000 from $369,000, reflecting higher costs associated with vendor advances and insurance as the company continues to operate as a public entity. For the nine-month period, total operating expenses reached $4.16 million, compared to $897,000 in 2024, with research and development expenses accounting for $1.6 million, up from $242,000.

In terms of financial position, Kairos Pharma reported total assets of $8.07 million as of September 30, 2025, a notable increase from $5.77 million at the end of 2024. The company’s cash and cash equivalents rose to $5.58 million, up from $1.27 million, bolstered by financing activities that included net proceeds of $3.06 million from a private financing round and $3.6 million from its equity line of credit. Shareholders' equity also improved to $7.66 million from $4.78 million, reflecting the issuance of additional common stock.

Strategically, Kairos Pharma has made significant moves to enhance its operational capabilities. The company has entered into various vendor agreements to support its clinical trials, including partnerships with Prevail Infoworks and PreCheck Health Services. Additionally, the company has expanded its equity incentive plan, granting restricted stock units to its executives and directors, which is expected to align their interests with those of shareholders. The company anticipates that its current cash reserves will sustain operations for at least the next 12 months, although it acknowledges the need for further capital to support ongoing development and operational costs.

Looking ahead, Kairos Pharma remains focused on advancing its clinical trials and securing regulatory approvals for its product candidates. The company recognizes the inherent risks and uncertainties in drug development and the necessity of raising additional funds to continue its operations. As it progresses, Kairos Pharma will rely on a combination of equity offerings, debt financing, and potential collaboration agreements to meet its financial needs and achieve its strategic objectives.